A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically
recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.